Publication:
DPP9 deficiency: An inflammasomopathy that can be rescued by lowering NLRP1/IL-1 signaling

Placeholder

Organizational Units

Program

KU Authors

Co-Authors

Harapas, Cassandra R.
Robinson, Kim S.
Lay, Kenneth
Wong, Jasmine
Traspas, Ricardo Moreno
Nabavizadeh, Nasrin
Rass-Rothschild, Annick
Boisson, Bertrand
Drutman, Scott B.
Laohamonthonkul, Pawat

Advisor

Publication Date

2022

Language

English

Type

Journal Article

Journal Title

Journal ISSN

Volume Title

Abstract

Dipeptidyl peptidase 9 (DPP9) is a direct inhibitor of NLRP1, but how it affects inflammasome regulation in vivo is not yet established. Here, we report three families with immune-associated defects, poor growth, pancytopenia, and skin pigmentation abnormalities that segregate with biallelic DPP9 rare variants. Using patient-derived primary cells and biochemical assays, these variants were shown to behave as hypomorphic or knockout alleles that failed to repress NLRP1. The removal of a single copy of Nlrp1a/b/c, Asc, Gsdmd, or Il-1r, but not Il-18, was sufficient to rescue the lethality of Dpp9 mutant neonates in mice. Similarly, dpp9 deficiency was partially rescued by the inactivation of asc, an obligate downstream adapter of the NLRP1 inflammasome, in zebrafish. These experiments suggest that the deleterious consequences of DPP9 deficiency were mostly driven by the aberrant activation of the canonical NLRP1 inflammasome and IL-1 ss signaling. Collectively, our results delineate a Mendelian disorder of DPP9 deficiency driven by increased NLRP1 activity as demonstrated in patient cells and in two animal models of the disease.

Description

Source:

Science Immunology

Publisher:

American Association for the Advancement of Science (AAAS)

Keywords:

Subject

Immunology

Citation

Endorsement

Review

Supplemented By

Referenced By

Copy Rights Note

0

Views

0

Downloads

View PlumX Details